R-Lipoic Acid for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

R-Lipoic Acid for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A sulfur compound the body makes inside its energy compartments; as a supplement it acts as a brief chemical signal switching on the cell's own protective machinery. Most consistent findings: relief of nerve symptoms in diabetes and modest improvements in insulin sensitivity, weight, body fat, and inflammation, mainly where starting values are abnormal. Nearly all testing used the blended form. (Full Review)

Protocol

Dose
100–300 mg/day R-form
Usually stabilised sodium R-lipoate. The standard racemic protocol is 600 mg/day; the two have never been compared head to head.
Timing
Morning, fasted
30 to 60 minutes before the first meal; food materially reduces total exposure. Single morning dosing is what the outcome data support.
Ceiling
300 mg R-form / 600 mg racemate
1,200 and 1,800 mg/day add adverse events without adding efficacy. Titration is half the target dose for the first two weeks.
Time to effect
Nerve symptoms
2–5 weeks
Fully expressed by five weeks; a halving of the symptom log score by week 5 matches the trial response threshold.
Insulin sensitivity
4–12 weeks
Duration-dependent rather than purely dose-dependent. No change in long-term glucose control is expected.
Body composition
24 weeks
Takes longest; the effect was largest at the final measurement, so judging it at 8 weeks is judging it too early.

Benefits

Contraindications
  • Known personal history of insulin autoimmune syndrome
  • Documented HLA-DRB1*04:03 or *04:06 genotype
  • Pregnancy and lactation
  • Thiamine deficiency or active alcohol use disorder
  • Chronic kidney disease stage 4 or worse (below 30 mL/min/1.73 m²)
  • Albumin-to-creatinine ratio above 30 mg/g
  • Any prior autoimmune endocrine disease
  • Children and adolescents (approximately 30 mg/kg toxicity threshold)
  • Within two weeks of elective surgery
    •
Key Interactions
  • Insulin and insulin secretagogues (sulfonylureas, meglitinides)
  • Other glucose-lowering agents (metformin, pioglitazone, SGLT2 inhibitors)
  • Thyroid hormone replacement (levothyroxine, liothyronine)
  • High-dose biotin
  • Over-the-counter medications (ibuprofen, naproxen, aspirin, antacids, proton pump inhibitors)
  • Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel)
  • Glucose-lowering supplements (berberine, chromium picolinate, cinnamon, gymnema)
  • Blood-pressure and platelet-active supplements (fish oil, garlic, nattokinase)
  • Metal supplements and chelators (iron, copper, zinc, dimercaptosuccinic acid, penicillamine)
  • Acetyl-L-carnitine, N-acetylcysteine, glycine
    •

Risk & Side Effects

  • High: Gastrointestinal intolerance
    •
  • Medium: Insulin autoimmune syndrome; hypoglycaemia with glucose-lowering therapy; acute overdose toxicity; proteinuria and kidney autoimmunity signal
  • Low: Skin reactions; biotin status depletion; strong urine odour
  • Speculative: Interference with thyroid function and thyroid testing; blunting of exercise training adaptations; depletion of essential trace minerals; pro-oxidant effects at high doses

Monitoring

Marker Target Why
Fasting insulin 2–5 µIU/mL The single most responsive marker
HOMA-IR < 1.5 Tracks insulin resistance directly
Fasting glucose 75–86 mg/dL Hypoglycaemia surveillance
HbA1c 4.8–5.4% Confirms no deterioration in average glucose
hs-CRP < 0.5 mg/L Primary inflammation readout
Fasting triglycerides < 80 mg/dL Entry criterion in the R-form trial and a response predictor
TSH and free T3 TSH 0.5–2.0 mIU/L; free T3 3.0–4.0 pg/mL Detects reported interference with thyroid function and conversion
Urine albumin-to-creatinine ratio < 10 mg/g Detects the proteinuria signal from long-term high-dose use
eGFR > 90 mL/min/1.73 m² Kidney reserve, and a gate on dosing
Complete blood count Within reference range Captures the leukocyte and platelet changes seen with R-lipoic acid
Ferritin and serum copper Ferritin 50–150 ng/mL; copper within reference range Guards against the theoretical chelation-driven mineral depletion

Cadence: Full panel at baseline before the first dose; fasting glucose self-checks in weeks 1, 2, and 4 for anyone on glucose-lowering medication; full repeat panel at 12 weeks; second full panel at 24 weeks; thereafter every 6 to 12 months, tightened to every 3 months for kidney markers if the daily dose exceeds 600 mg of racemate.

Qualitative Assessment

  • Neuropathic symptoms: burning pain, stabbing pain, pins-and-needles sensation, and numbness in the feet, each rated 0–3 for intensity and frequency
  • Energy and exercise tolerance: perceived daytime energy and whether habitual training sessions feel easier or harder
  • Appetite and satiety: meal size and between-meal hunger
  • Cognitive clarity: subjective focus and word-finding
  • Gastrointestinal tolerance: nausea, reflux, and heartburn
  • Sleep quality and timing of any disturbance: specifically whether disturbance clusters after an evening dose
  • Skin: any new rash, itching, or hives
  • Urine odour: noted once so it is not later mistaken for infection or toxicity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.